Sale
Massive Discounts! Up to 50% OFF on reports🎉

Oral Anti Diabetes Drugs Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: February 2024 || SKU: PH2726
excelpdfpowerpoint
180 pages
Report Summary
Table of Content
List of Tables & Figures
Download Free Sample

Oral Anti Diabetes Drugs Market is segmented By Drug Class (Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors, Sulfonylureas, Meglitinides), By Dosage Type (Liquid, Capsule, Tablet), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, South America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

 

Oral Anti Diabetes Drugs Market Size

The Global Oral Anti-Diabetic Drugs Market reached USD 44.3 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 80.8 billion by 2031. The global oral anti-diabetic drugs market is expected to exhibit a CAGR of 8.0% during the forecast period (2024-2031). The most prevalent form of diabetes, type 2 diabetes mellitus, is managed and treated mostly with the help of oral anti-diabetic medications.

People with type 2 diabetes who do not need insulin therapy or who have not achieved optimal glycemic control through lifestyle changes alone are often administered these drugs. To obtain the best blood glucose control, oral anti-diabetes medications may occasionally be combined with insulin or other injectable therapy. 

 

Oral Anti Diabetes Drugs Market Scope

Metrics

Details

CAGR

8.0%

Size Available for Years

2022-2031

Forecast Period

2024-2031

Data Availability

Value (US$) 

Segments Covered

Product, Dosage Type, Distribution Channel, and Region

Regions Covered

North America, Europe, Asia-Pacific, South America, and Middle East & Africa

Fastest Growing Region

Asia-Pacific

Largest Region

North America

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Orthopedic Surgery key Insights.

 

For More Insights - Request Free Sample

 

Oral Anti Diabetes Drugs Market Dynamics

The Increasing Prevalence Of Diabetes Is Driving The Global Oral Anti-Diabetic Drug Market Growth. 

Diabetes Mellitus (DM) affects people all over the world. It is a metabolic condition marked by persistently elevated blood sugar levels brought on by either insulin hormone resistance or shortage. As per the article published in Cureus in 2022, approximately 463 million cases of diabetes mellitus (DM) were reported globally in persons aged 20 to 79 in 2019. By 2030 and 2045, these numbers are predicted to increase to 578 million and up to 700 million, respectively.

Wide-ranging effects result from diabetes's rising prevalence. Diabetes is a chronic disease that can cause a number of side effects, such as heart disease, kidney issues, nerve damage, and eye impairment. Since diabetes requires long-term management and treatment, including drugs, consistent monitoring, and healthcare services, it has a major financial impact.

The Growing Aging Population Is Driving The Global Oral Anti-Diabetic Drug Market Growth. 

Diabetes is becoming more prevalent in persons 65 and older as the population as a whole continues to age. According to the WHO, the percentage of people over 60 in the world's population will nearly double from 12% to 22% between 2015 and 2050. Additionally, research from the Endocrine Society from January 2022 estimates that 33% of persons 65 and older have diabetes. 

Compared to younger people with diabetes, this population is more susceptible to developing problems such as hypoglycemia (low blood sugar), renal failure, and heart disease.  Age-related diseases like cognitive impairment, cardiovascular disease, and others that affect diabetes education and care are frequently present in older persons.  

Side Effects Associated With Diabetes Treatment Are Hampering The Global Oral Anti-Diabetic Drugs Market Growth.

Oral anti-diabetic medications can help people with type 2 diabetes control their blood glucose levels, but they also have certain potential side effects. The intensity and frequency of these side effects might vary. Some oral anti-diabetic medications, particularly sulfonylureas, and meglitinides, can cause hypoglycemia (low blood sugar) by significantly lowering blood glucose levels. 

Hypoglycemia can cause hunger, disorientation, shakiness, dizziness, and other symptoms. It is critical for people taking these medications to periodically check their blood sugar levels and be alert to the warning signs and symptoms of hypoglycemia.

Oral Anti Diabetes Drugs Market Segment Analysis

The global oral anti-diabetic drugs market is segmented based on drug class, dosage type distribution channel, and region.

The Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors Segment Is Expected To Hold One Of The Dominant Position In The Market Over The Forecast Period.

The Dipeptidyl Peptidase - 4 (DPP-4) inhibitors segment accounted for the 2nd highest market stake accounting for approximately 33.6% of the oral anti-diabetic drugs market in 2022. As per the article published in Statperls in 2023, the incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (gastric inhibitory peptide), which increase insulin secretion and decrease glucagon secretion to maintain glucose homeostasis, are primarily affected by the ubiquitous enzyme DPP-4.

The small intestine's enteroendocrine L cells secrete the hormone GLP-1, which decreases blood sugar by promoting the release of more insulin, lowering glucagon levels, and delaying the emptying of the stomach. The half-life is under two minutes. Neuroendocrine K-cells release the hormone GIP in the stomach and proximal small intestine. In healthy people, its half-life is roughly 7 minutes, but in people with type 2 diabetes, it is 5 minutes.

Source: DataM Intelligence Analysis (2023)

 

Oral Anti Diabetes Drugs Market Geographical Share

North America Holds A Dominant Position In The Global Oral Anti-Diabetic Drugs Market.

North America is estimated to hold around 37.8% of the total market share throughout the forecast period. Owing to the aging population in the region is increasing, and the increasing prevalence of diabetes boosts the regional growth over the forecast period. The prevalence of diabetes is rising alarmingly in the US. According to the CDC's National Diabetes Statistics Report, 11.3% of Americans, or 37.3 million people, have diabetes. 28.5% of the population, or an estimated 28.7 million people, had diabetes.  

By 2022, 8.5 million people with diabetes will not have received a diagnosis. Every social, economic, and racial background is impacted by diabetes. T1D affects 1.45 million Americans or roughly 3.75% of all instances of diabetes that have been diagnosed. Newer and more potent oral anti-diabetes medications have been made available as a result of improvements in pharmaceutical research and development. Market expansion is facilitated by the creation of novel formulations and delivery mechanisms like sustained-release tablets or combo medicines.

Source: DataM Intelligence Analysis (2023)

 

Oral Anti Diabetes Drugs Market Key Players

The major global players in the market include Glenmark Pharma, Abbott, Biocon, Sanofi S.A., Sunpharma, Novartis, Novo Nordisk, Merck, GlaxoSmithKline, and Bristol-Myers Squibb among others.

 

Russia Ukraine Conflict Analysis

The Russia-Ukraine war may affect the oral anti-diabetic drugs market due to a lack of healthcare facilities being impacted during times of geopolitical instability and economic uncertainty. Hospitals, clinics, and pharmacies in the impacted sectors experienced stress as a result of the conflict. This strain may affect the ability of the entire healthcare system to give patients access to oral diabetic medications and proper treatment. 

The conflict might take resources and focus away from work on research and development for oral diabetes medications. Pharmacies and research facilities in the impacted sectors faced challenges when trying to collaborate with foreign partners, engage in innovation, or conduct clinical trials. 

Artificial Intelligence Analysis

Artificial intelligence (AI) is increasingly being used in the oral anti-diabetic drugs market to improve various aspects of drug discovery. AI can aid in the creation of personalized medicine strategies for the management of diabetes. AI algorithms can help in the customization of oral anti-diabetes pharmacological therapy for specific patients by examining patient data, including medical history, genetic information, lifestyle factors, and medication response. This can improve treatment results and reduce negative effects. 

Key Developments

  • In January 2023, Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, reported top-line results from the Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial (ORA-D-013-1) comparing the efficacy of ORMD-0801 to placebo in patients with Type 2 Diabetes (T2D) at 26 weeks. 710 patients with T2D and insufficient glycemic control on two or three oral glucose-lowering medications were enrolled in ORA-D-013-1.
  • In July 2022, for people with type 2 diabetes, Glenmark Pharmaceuticals Limited introduced sitagliptin and its Fixed Dose Combinations (FDCs) in India. Under the brand name SITAZIT and its variations, Glenmark made available eight alternative combinations of sitagliptin-based medications for a reasonable price.

 

Why Purchase the Report?

  • To visualize the global oral anti-diabetic drugs market segmentation based on the drug class, dosage type, distribution channel, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development. 
  • Excel data sheet with numerous data points of oral anti-diabetic drugs market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global oral anti-diabetic drugs market report would provide approximately 62 tables, 61 figures, and 195 Pages.

Target Audience 2024

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies
Buy this report
Single User
$4350$3480
Multiple User
$4850$3880
Enterprise User
$7850$6280
Proceed to Buy
  Get Free Sample
  Request new version
  Customize Sample
  Demo Full Report
FAQ’s

Related Reports
pharmaceuticals iconpharmaceuticals

Basal Insulin (Long-Acting Insulin) Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 November 11

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Oral Anti Diabetes Drugs Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 February 20

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Diabetes Therapeutics Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 June 19

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Diabetic Neuropathy Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2025 February 21

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Type 2 Diabetes Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 December 27

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Diabetic Neuropathic Foot Ulcers Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 September 04

Starting from

$4350